GlassScriptPhysician profile
Steven R Plunkett
NPI 1750350112
$483.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $215 · 2021: $121 · 2022: $12.67 · 2023: $41.10 · 2024: $93.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $134.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $71.81 | 2020-2024 | Imbruvica, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $62.52 | 2020-2024 | |
| Celgene Corporation | $50.06 | 2020-2021 | |
| Taiho Oncology, INC. | $36.85 | 2020-2021 | |
| Genzyme Corporation | $29.00 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.94 | 2020-2021 | |
| Tersera Therapeutics LLC | $25.38 | 2023 | Zoladex |
| Amgen INC. | $24.70 | 2021 | |
| Aveo Pharmaceuticals, INC. | $23.39 | 2024 | |
| Astellas Pharma US INC | $19.30 | 2020 | |
| Pharmacosmos Therapeutics INC. | $18.80 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.54 | 2021 | |
| Novocure INC. | $17.17 | 2020 | |
| Genentech USA, INC. | $16.44 | 2024 | Polivy |
| Pharmacyclics LLC, An Abbvie Company | $14.71 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $14.42 | 2020 | |
| Merck Sharp & Dohme LLC | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Plunkett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.